Vice Chairman

Mark Sorrentino, MD, MS
Vice President, Scientific Affairs, PRA Health Sciences

Mark Sorrentino, MD, MS, has 20 years of experience in the pharmaceutical and biotech industries. He is currently the Vice President, Scientific Affairs at PRA Health Sciences and leads the global pediatric center of excellence.

Prior to joining PRA, Dr. Sorrentino spent 5 years as the global chair and founder of the pediatric practice area overseeing all aspects of strategy and clinical development in pediatrics. He was also the global therapeutic head of critical care.

Before joining PPD Dr. Sorrentino was the global Chief Medical Officer at ADMA Biologics where he oversaw all clinical development operations. Prior to ADMA, Dr. Sorrentino was the Director, Medical Science at MedImmune where he had primary responsibility for development and oversight of numerous Phase IV and post-marketing studies across several therapeutic areas including infectious diseases, respiratory diseases, and transplant medicine, and worked closely with the sales and marketing teams.

Dr. Sorrentino has also served as a consultant to biotechnology firms and has overseen implementation of medical information systems. Dr. Sorrentino received his MD as well an MS in Clinical Nutrition from the Chicago Medical School. He completed both a residency in Pediatrics and fellowship in Pediatric Critical Care at Children’s National Medical Center in Washington DC and currently holds an appointment as an Assistant Clinical Professor at the George Washington University School of Medicine. Dr. Sorrentino was an attending physician in the CNMC pediatric intensive care unit for 8 years and participated in numerous Industry sponsored critical care trials.

Dr. Sorrentino holds active medical licenses in Washington DC and Maryland. He also serves as the Medical Director for all Susan G. Komen events in the DC area and has volunteered on several international medical missions. He is an active medical team member of Team Rubicon and sits on the Maryland Responds advisory board.